ScreenerHero

ACHVAchieve Life Sciences, Inc.

NAS · US · Healthcare · Biotechnology · achievelifesciences.com
7.990USDMkt Cap: 822.19M $P/E: —

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap822.19M $
Enterprise Value649.84M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-54.65M $
Revenue/Share—
Last Price7.990 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0044685008
Valuation
P/E (Trailing)—
P/E (Forward)-12.56
PEG17.68
EV/EBITDA-11.19
EV/Revenue—
P/S—
P/B-55.87
EPS (TTM)-1.66
EPS (Forward)-0.64
52W Range
7.90031% of range8.194
52W High8.194 USD
52W Low7.900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-253.96%
ROA-130.77%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-49.47M $
CapEx (TTM)4.00K $
FCF Margin—
FCF Yield19.01%
Net Debt-172.36M $
Net Debt/EBITDA2.97
Balance Sheet
Debt/Equity0.69
Current Ratio0.95
Quick Ratio0.95
Book Value/Sh-0.1430 USD
Cash/Share1.820 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 31, 2020
Splits
Last Split1:20
Split DateJul 31, 2020
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.83 USD
Upside (mean)+73.1%
Target Range9.000 USD – 21.00 USD
$9.000+73.1% to mean$21.00
# Analysts12
Ownership
Shares Out.102.90M
Float73.93M
Insiders0.93%
Institutions81.95%
Short Interest
Short Ratio10.7d
Short % Float15.94%
Short % Out.15.85%
Shares Short16.27M
Short (prev mo.)12.58M
Technical
SMA 506.350 (+25.8%)
SMA 2004.966 (+60.9%)
Beta2.23
S&P 52W Chg19.18%
Avg Vol (30d)1.06M
Avg Vol (10d)1.72M
Technical Indicators
RSI (14)68.4
MACD0.4955
MACD Signal0.3657
MACD Hist.+0.1298
BB Upper8.333 USD
BB Middle6.922 USD
BB Lower5.511 USD
BB Width40.77%
ATR (14)0.4194 USD
Vol Ratio (20d)0.79x